
Johnson & Johnson seeks to buy eye disease biotech for up to $3.4 billion
Unlock Editor’s Digest for free
Roula Khalaf, editor-in-chief of the FT, selects her favorite stories in this weekly newsletter.
Johnson & Johnson is set to buy a private developer of eye disease drugs for up to $3.4 billion, the latest in a series of targeted acquisitions in the biotechnology sector.
The New Jersey-based pharmaceutical maker could announce a deal to buy Ollin Biosciences as soon as Monday, according to people familiar with the matter.
Under the terms of the deal under discussion, J&J could pay Ollin’s backers $2.2 billion in cash upfront and an additional $1.2 billion in potential milestone payments, the sources added. However, they warned that the negotiations could still fail.
Ollin, backed by investment firms Arch Venture Partners and Mubadala Capital, is developing a drug to treat two major causes of severe vision loss later in life.
The potential deal comes as the pharmaceutical industry prepares to head to London this week for the annual Jefferies Healthcare Summit, a marquee gathering of executives, investors and advisors.
A record 46 biotechs valued at more than $1 billion have been sold so far this year, eclipsing the previous annual record of 35, according to investment bank Stifel.
After a busy first half, in which $131.5 billion in biotech deals were completed, deals have slowed in recent months, with only $44.8 billion in deals in the second half to date.
J&J has been among the most active acquirers, striking a $1 billion deal to buy oncology drug developer Firefly Bio earlier this year and a $14.6 billion buyout of psychiatry-focused biotech intracellular therapies early last year.
J&J’s shares are up 38 percent year to date, giving it a market capitalization of nearly $688 billion as of Friday’s close.
An acquisition of Ollin would give J&J a beachhead in drugs to treat retinal diseases, an area in which the pharmaceutical maker has a limited presence despite its large contact lens sales business.
Ollin’s lead drug, OLN324, is expected to be studied in late-stage trials as a treatment for wet age-related macular degeneration and diabetic macular edema, both of which can cause serious vision impairment.
Several major pharmaceutical groups have moved into the eye disease drug business in recent years, with drugmakers like Merck and Bayer buying up early-stage companies. Regeneron’s retinal disease drug Eylea has proven to be one of the most effective blockbuster drugs of all time.
Ollin raised $330 million earlier this year to fund its upcoming Phase 3 trials. Its backers also include biotech venture capital firms TCGX, RA Capital and Monograph Capital.
J&J declined to comment while Ollin did not respond to requests for comment.
Gn bussni